Nuvectis Pharma, Inc.
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
NVCT$20.91+17.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Developments
Recent Developments
| · | Completed in licensing of two potentially best-in-class drug candidates from Haisco Pharmaceutical Group and follow-on public offering anchored by leading healthcare investors. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.